

APR. 29. 2005 10:35AM AVENTIS US PAT DEPT
T.O: US USPTO GENERAL


RECEIVED
CENTRAL FAX CENTER NO. 4825 P. 1/12
APR 29 2005


PTO/SB/21 (08-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/616,945	
	Filing Date	July 11, 2003	
	First Named Inventor	Heiner GLOMBIK et al.	
	Art Unit	1623	
	Examiner Name	E. Preselev	
Total Number of Pages in This Submission	12	Attorney Docket Number	DEAV2002/0049 US NP

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	Remarks	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm Name	AVENTIS PHARMACEUTICALS INC.
Signature	
Printed name	Joseph D. Rossi
Date	April 29, 2005
Reg. No.	47,038

CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 703-872-9306; Total No. of Pages Transmitted: 12)	
Signature	
Typed or printed name	Paul Irvine
Date	April 29, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

DEAV2002/0049 US NP

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICEIn re Application of
GLOMBIK, et al.

Examiner: E. Preselev

RECEIVED
CENTRAL FAX CENTER

Application No.: 10/616,945

Art Unit: 1623

APR 29 2005

Filed: July 11, 2003

Title: **Novel Thiophene Glycoside Derivatives,
Processes for Their Preparation,
Medicaments Comprising These
Compounds, and The Use Thereof****TELEFAX CERTIFICATE**I hereby certify that this correspondence is being
transmitted via facsimile to the Commissioner for
Patents, Alexandria, VA 22313, on

April 29, 2005

Date of Transmission

Signature Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450**REPLY PURSUANT TO 37 C.F.R. §1.111**

Dear Sir:

In response to the Official Action dated February 2, 2005 ("the Action"),
reconsideration is respectfully requested in view of the amendments and/or remarks as indicated
below:

Amendments to the Claims are reflected in the listing of the claims that begins on
page 2 of this paper.

Remarks/Arguments begin on page 10 of this paper.